Multi-year, 1143-patient genetic study identified unique types of multiple myeloma
On Aug. 19, 2024, an international team of scientists led by researchers from the Translational Genomics Research Institute (TGen) announced…
On Aug. 19, 2024, an international team of scientists led by researchers from the Translational Genomics Research Institute (TGen) announced…
On May 15, 2024, the American Association for Cancer Research (AACR) released its biennial Cancer Disparities Progress Report…
On Mar. 27, 2021, the FDA approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients…
On Mar. 26, 2021, Bristol Myers Squibb and bluebird bio announced that the FDA had approved Abecma (idecabtagene…
On May 1, 2020, Janssen Pharma, a Johnson & Johnson company, announced the U.S. Food and Drug Administration…
On Apr. 7, 2020, Karyopharm Therapeutics announced plans to initiate a global randomized clinical trial for low dose…
On Mar. 9, 2020, Winship Cancer Institute’s multiple myeloma team was awarded a $5 million grant from The…
On Nov. 29, 2018, St. Louis native Rodger Riney and his wife, Paula, donated $20 million to research…
On Dec. 3, 2016, Celgene, Dana-Farber Cancer Institute and the University of Arkansas for Medical Sciences announced the…
On Aug. 9, 2011, the Siteman Cancer Center announced that it had performed its 5,000th bone marrow transplant,…
On Jun. 22, 2008, National Cancer Institute researchers announced that cells from a blood-borne cancer called multiple myeloma…
On May 13, 2003, the FDA approved the drug bortezomib (Velcade) for the treatment of multiple myeloma. In…
On May 14, 2002, President George W. Bush signed the Hematologic Cancer Research Investment and Education Act of…